Literature DB >> 28418656

Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.

John M Sanders1, Douglas C Beshore1, J Christopher Culberson1, James I Fells1, Jason E Imbriglio1, Hakan Gunaydin1, Andrew M Haidle1, Marc Labroli1, Brian E Mattioni1, Nunzio Sciammetta1, William D Shipe1, Robert P Sheridan1, Linda M Suen1, Andreas Verras1, Abbas Walji1, Elizabeth M Joshi1, Tjerk Bueters1.   

Abstract

High-throughput screening (HTS) has enabled millions of compounds to be assessed for biological activity, but challenges remain in the prioritization of hit series. While biological, absorption, distribution, metabolism, excretion, and toxicity (ADMET), purity, and structural data are routinely used to select chemical matter for further follow-up, the scarcity of historical ADMET data for screening hits limits our understanding of early hit compounds. Herein, we describe a process that utilizes a battery of in-house quantitative structure-activity relationship (QSAR) models to generate in silico ADMET profiles for hit series to enable more complete characterizations of HTS chemical matter. These profiles allow teams to quickly assess hit series for desirable ADMET properties or suspected liabilities that may require significant optimization. Accordingly, these in silico data can direct ADMET experimentation and profoundly impact the progression of hit series. Several prospective examples are presented to substantiate the value of this approach.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28418656     DOI: 10.1021/acs.jmedchem.6b01577

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial and Transmission Blocking Activities.

Authors:  Marilia N N Lima; Cleber C Melo-Filho; Gustavo C Cassiano; Bruno J Neves; Vinicius M Alves; Rodolpho C Braga; Pedro V L Cravo; Eugene N Muratov; Juliana Calit; Daniel Y Bargieri; Fabio T M Costa; Carolina H Andrade
Journal:  Front Pharmacol       Date:  2018-03-06       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.